)
Kymera Therapeutics (KYMR) investor relations material
Kymera Therapeutics AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Opening remarks and agenda
Chairperson welcomed attendees and introduced board members and executive officers present at the meeting.
The independent registered public accounting firm, Ernst & Young, was introduced.
The meeting agenda was outlined, referencing the Notice of Annual Meeting and Proxy Statement.
Board and executive committee updates
Board members and executive officers were formally introduced, including roles such as Chief Legal Officer, Chief Medical Officer, Chief Business Officer, and Chief Financial Officer.
Shareholder proposals
Proposal 1: Election of four Class III directors to serve until the 2029 annual meeting.
Proposal 2: Non-binding advisory vote to approve named executive officer compensation.
Proposal 3: Ratification of Ernst & Young as independent registered public accounting firm for fiscal year ending December 31, 2026.
- KT-621 achieved >90% STAT6 degradation, strong Th2 biomarker reduction, and excellent safety.KYMR
Study Result9 Jul 2026 - KT-474 Phase 2 expansion, strong pipeline data, and $702M cash runway highlight Q2 2024.KYMR
Q2 20249 Jul 2026 - Pipeline advanced, strong cash reserves, and major clinical milestones expected in 2025.KYMR
Q4 20249 Jul 2026 - Oral degraders advance in AD and asthma, showing strong efficacy and safety in early trials.KYMR
44th Annual J.P. Morgan Healthcare Conference9 Jul 2026 - KT-621 and TYK2 degraders advance with pivotal trials and major data readouts set for 2024.KYMR
TD Cowen 45th Annual Healthcare Conference8 Jul 2026 - STAT6 and IRF5 programs drive pipeline growth, targeting large unmet needs in Type 2 diseases.KYMR
Oppenheimer 36th Annual Healthcare Life Sciences Conference8 Jul 2026 - Accelerated immunology pipeline targets broad indications with strong biomarker and clinical strategy.KYMR
Citi Annual Global Healthcare Conference 20258 Jul 2026 - Q3 net loss of $62.5M; $911M cash supports immunology focus and clinical milestones into 2027.KYMR
Q3 20248 Jul 2026 - KT-621, an oral STAT6 degrader, leads a pipeline poised to transform Th2 disease treatment.KYMR
Citi's Biopharma Back to School Conference8 Jul 2026 - Oral protein degraders advance in immunology with robust pipeline and strong financial runway.KYMR
Jefferies London Healthcare Conference 20258 Jul 2026
Next Kymera Therapeutics earnings date
Next Kymera Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)